The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2024

Filed:

Apr. 27, 2018
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université Paul Sabatier Toulouse Iii, Toulouse, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;

Ecole Nationale Vétérinaire DE Toulouse, Toulouse, FR;

Inventors:

Nicolas Cenac, Toulouse, FR;

Justine Bertrand-Michel, Toulouse, FR;

Teresa Perez-Berezo, Toulouse, FR;

Thierry Durand, Montpellier, FR;

Jean-Marie Galano, Montpellier, FR;

Julien Pujo, Toulouse, FR;

Eric Oswald, Toulouse, FR;

Patricia Martin, Toulouse, FR;

Pauline Le Faouder, Toulouse, FR;

Alexandre Guy, Montpellier, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 233/47 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
C07C 233/47 (2013.01); A61P 29/00 (2018.01);
Abstract

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probioticstrain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.


Find Patent Forward Citations

Loading…